Neutralizing anti-influenza virus monoclonal antibodies: Therapeutics and tools for discovery

International Reviews of Immunology

Volumn 28, Issue 1-2, 2009, Pages 69-92

  Martinez, Osvaldo ^a   Tsibane, Tshidi ^a   Basler, Christopher F ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody; Influenza virus; Memory B cell; Monoclonal

Indexed keywords

B LYMPHOCYTE RECEPTOR; HUMAN MONOCLONAL ANTIBODY; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; OKT 3; PALIVIZUMAB; VIRUS ANTIBODY;

ANTIBODY RESPONSE; B LYMPHOCYTE; CELL SELECTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INNATE IMMUNITY; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS TRANSMISSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC MEMORY; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE; PEPTIDE LIBRARY;

EID: 60849088256     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.1080/08830180802593540     Document Type: Review

References (69)

1. L. Megan and P.P. Shaw, Orthomyxoviridae: The Viruses and Their Replication. Philadelphia: Lippincott Williams and Wilkins, 2007.
2. A.H. Reid and J.K. Taubenberger, The origin of the 1918 pandemic influenza virus: A continuing enigma J Gen Virol 84: 2285-2292, 2003.
3. R. Ahmed, M.B. Oldstone, and P. Palese, Protective immunity and susceptibility to infectious diseases: Lessons from the 1918 influenza pandemic. Nat Immunol 8: 1188-1193, 2003.
4. A. Casadevall and M.D. Scharff, Return to the past: The case for antibody-based therapies in infectious diseases. Clin Infect Dis 21: 150-161, 1995.
5. R.A. Good and E. Lorenz, Historic aspects of intravenous immunoglobulin therapy. Cancer 68: 1415-1421, 1991.
6. T.C. Luke, E.M. Kilbane, J.L. Jackson, and S.L. Hoffman, Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? Ann Intern Med 145: 599-609, 2006.
7. J.P. Wang, E.A. Kurt-Jones, and R.W. Finberg, Innate immunity to respiratory viruses. Cell Microbiol 9: 1641-1646, 2007.
8. A. Fernandez-Sesma and T.M. Moran, Role of the influenza virus nonstructural 1 protein in evasion of immunity. Future Virol 2: 389-399, 2007.
9. P.G. Thomas, R. Keating, D.J. Hulse-Post, and P.C. Doherty, Cell-mediated protection in influenza infection. Emerg Infect Dis 12: 48-54, 2006.
10. W. Gerhard, The role of the antibody response in influenza virus infection. Curr Top Microbiol Immunol 260: 171-190, 2001.
11. W. Gerhard, K. Mozdzanowska, M. Furchner, G. Washko, and K. Maiese, Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol Rev 159: 95-103, 1997.
12. D.M. Tarlinton, Evolution in miniature: Selection, survival, and distribution of antigen reactive cells in the germinal centre. Immunol Cell Biol 86: 133-138, 2008.
13. S.A. Reading and N.J. Dimmock, Neutralization of animal virus infectivity by antibody. Arch Virol 152: 1047-1059, 2007.
14. M. Knossow, M. Gaudier, A. Douglas, et al., Mechanism of neutralization of influenza virus infectivity by antibodies. Virology 302: 294-298, 2002.
15. K. Mozdzanowska, K. Maiese, M. Furchner, and W. Gerhard, Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 254: 138-146, 1999.
16. G. Palladino, K. Mozdzanowska, G. Washko, and W. Gerhard, Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol 69: 2075-2081, 1995.
17. M.M. Putz, I. Alberini, C.M. Midgley, I. Manini, E. Montomoli, and G.L. Smith, Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy. J Gen Virol 86: 2955-2960, 2005.
18. S. Crotty, P. Felgner, H. Davies, J. Glidewell, L. Villarreal, and R. Ahmed, Cutting edge: Long-term B cell memory in humans after smallpox vaccination. J Immunol 171: 4969-4973, 2003.
19. X. Yu, Neutralizing antibodies derived from the B cells of 1918 pandemic survivors. Nature 455: 532-536, 2008.
20. R.A. Manz, A.E. Hauser, F. Hiepe, and A. Radbruch, Maintenance of serum antibody levels. Annu Rev Immunol 23: 367-386, 2005.
21. R.A. Manz, A. Thiel, and A. Radbruch, Lifetime of plasma cells in the bone marrow. Nature 388: 133-134, 1997.
22. M.K. Slifka, R. Antia, J.K. Whitmire, and R. Ahmed, Humoral immunity due to long-lived plasma cells. Immunity 8: 363-372, 1998.
23. A. Lanzavecchia, N. Bernasconi, E. Traggiai, C.R. Ruprecht, D. Corti, and F. Sallusto, Understanding and making use of human memory B cells. Immunol Rev 211: 303-309, 2006.
24. R.A. Manz and A. Radbruch, Plasma cells for a lifetime? Eur J Immunol 32: 923-927, 2002.
25. J.A. Brieva, E. Roldan, M.L. De la Sen, and C. Rodriguez, Human in vivo-induced spontaneous IgG-secreting cells from tonsil, blood, and bone marrow exhibit different phenotype and functional level of maturation. Immunology 72: 580-583, 1991.
26. K. Tokoyoda, T. Egawa, T. Sugiyama, B.I. Choi, and T. Nagasawa, Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 20: 707-718, 2004.
27. W. Gerhard, The analysis of the monoclonal immune response to influenza virus. II. The antigenicity of the viral hemagglutinin. J Exp Med 144: 985-995, 1976.
28. M.L. Shaw and P. Palese, Lippincott Williams & Wilkins, 2007.
29. World Health Organization. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1). Reported to WHO, Geneva, 2008.
30. A.J. Caton, G.G. Brownlee, J.W. Yewdell, and W. Gerhard, The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31: 417-427, 1982.
31. F.L. Raymond, A.J. Caton, N.J. Cox, A.P. Kendal, and G.G. Brownlee, Antigenicity and evolution amongst recent influenza viruses of H1N1 subtype. Nucl Acids Res 11: 7191-7203, 1983.
32. G.W. Both, M.J. Sleigh, N.J. Cox, and A.P. Kendal, Antigenic drift in influenza virus H3 hemagglutinin from 1968 to 1980: Multiple evolutionary pathways and sequential amino acid changes at key antigenic sites. J Virol 48: 52-60, 1983.
33. D.C. Wiley, I.A. Wilson, and J.J. Skehel, Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289: 373-378, 1981.
34. H. Fuller and C. Del Mar, Immunoglobulin treatment for respiratory syncytial virus infection. Cochrane Database Syst Rev CD004883, 2006.
35. V.G. Hemming, Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases. Clin Diagn Lab Immunol 8: 859-863, 2001.
36. W.A. Marasco and J. Sui, The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 25: 1421-1434, 2007.
37. A. Lanzavecchia, D. Corti, and F. Sallusto, Human monoclonal antibodies by immortalization of memory B cells. Curr Opin Biotechnol 18: 523-528, 2007.
38. A.K. Kashyap, J. Steel, A.F. Oner, et al., Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci USA 105: 5986-5991, 2008.
39. C.F. Basler and P.V. Aguilar, Progress in identifying virulence determinants of the 1918 H1N1 and the Southeast Asian H5N1 influenza A viruses. Antiviral Res 79: 166-178, 2008.
40. World Health Organization. Towards a unified nomenclature system for the highly pathogenic H5N1 avian influenza viruses, Geneva, 2007.
41. W.L. Wu, Y. Chen, P. Wang, et al., Antigenic profile of avian H5N1 viruses in Asia from 2002 to 2007. J Virol 82: 1798-1807, 2008.
42. M. Throsby, C. Geuijen, J. Goudsmit, et al., Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol 80: 6982-6992, 2006.
43. J. ter Meulen, A.B. Bakker, E.N. van den Brink, et al., Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 363: 2139-2141, 2004.
44. J. ter Meulen, E.N. van den Brink, L.L. Poon, et al., Human monoclonal antibody combination against SARS coronavirus: Synergy and coverage of escape mutants. PLoS Med 3: e237, 2006.
45. P.-J. Meijer, P.S. Andersen, M. Haahr Hansen, et al., Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing. J. Mol Biol 358: 764-772, 2006.
46. J.C. Almagro and J. Fransson, Humanization of antibodies. Front Biosci 13: 1619-1633, 2008.
47. E.A. Kabat, T.T. Wu, M. Reid-Miller, H.M. Perry, and K.S. Gottesman, Sequences of Proteins of Immunological Interest. Bethesda: National Institutes of Health, 1987.
48. M.P. Lefranc, The Immunoglobulin Facts Book. London: Academic Press, 2001.
49. B.J. Hanson, A.C. Boon, A.P. Lim, A. Webb, E.E. Ooi, and R.J. Webby, Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res 7: 126, 2006.
50. N.V. Kaverin, I.A. Rudneva, E.A. Govorkova, et al., Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J Virol 81: 12911-12917, 2007.
51. W. Gerhard, J. Yewdell, M.E. Frankel, and R. Webster, Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 290: 713-717, 1981.
52. D.C. Wiley and J.J. Skehel, The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem 56: 365-394, 1987.
53. N.V. Kaverin, I.A. Rudneva, N.A. Ilyushina, A.S. Lipatov, S. Krauss, and R.G. Webster, Structural differences among hemagglutinins of influenza A virus subtypes are reflected in their antigenic architecture: Analysis of H9 escape mutants. J Virol 78: 240-249, 2004.
54. N.V. Kaverin, I.A. Rudneva, N.A. Ilyushina, et al., Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants. J Gen Virol 83: 2497-2505, 2002.
55. M. Coughlin, G. Lou, O. Martinez, et al., Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse. Virology 361: 93-102, 2007.
56. S.E. Sloan, C. Hanlon, W. Weldon, et al., Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine 25: 2800-2810, 2007.
57. T.C. Greenough, G.J. Babcock, A. Roberts, et al., Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis 191: 507-514, 2005.
58. Y. He, W.J. Honnen, C.P. Krachmarov, et al., Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci. J Immunol 169: 595-605, 2002.
59. World Health Organization. Cumulative Number of Reported Cases (SARS).
60. World Health Organization. Rabies Fact Sheet No. 99, 2006, Geneva.
61. J.P. DeVincenzo, C.B. Hall, D.W. Kimberlin, et al., Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) resistant mutants. J Infect Dis 190: 975-978, 2004.
62. A. Jakobovits, R.G. Amado, X. Yang, L. Roskos, and G. Schwab, From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 25: 1134-1143, 2007.
63. N. Nagata, N. Iwata, H. Hasegawa, et al., Mouse-passaged severe acute respiratory syndrome-associated coronavirus leads to lethal pulmonary edema and diffuse alveolar damage in adult but not young mice. Am J Pathol 172: 1625-1637, 2008.
64. J. Wrammert, K. Smith, J. Miller, et al., Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453: 667-671, 2008.
65. C.P. Simmons, N.L. Bernasconi, A.L. Suguitan, et al., Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 4: e178, 2007.
66. C. Tian, G.K. Luskin, K.M. Dischert, J.N. Higginbotham, B.E. Shepherd, and J.E. Crowe, Jr. Evidence for preferential Ig gene usage and differential TdT and exonuclease activities in human naive and memory B cells. Mol Immunol 44: 2173-2183, 2007.
67. T.M. Tumpey, C.F. Basler, P.V. Aguilar, et al., Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310: 77-80, 2005.
68. J. Stevens, A.L. Corper, C.F. Basler, J.K. Taubenberger, P. Palese, and I.A. Wilson, Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 303: 1866-1870, 2004.
69. S.J. Gamblin, L.F. Haire, R.J. Russell, et al., The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science 303: 1838-1842, 2004.